{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:43:46Z","timestamp":1794228226769,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/101649X1"],"award-info":[{"award-number":["BB\/101649X1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12917-017-1128-y","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T21:50:54Z","timestamp":1498859454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic\/pharmacodynamic modelling"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-7919","authenticated-orcid":false,"given":"Lucy","family":"Dorey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Pelligand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"issue":"6","key":"1128_CR1","doi-asserted-by":"crossref","first-page":"p523","DOI":"10.1111\/jvp.12125","volume":"37","author":"M Schneider","year":"2014","unstructured":"Schneider M, Paulin A, Dron F, Woehrle F. Pharmacokinetic of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg\/kg: dose proportionality, influence of the age of the animals and urinary elimination. J Vet Pharmacol and Ther. 2014;37(6):p523\u201330.","journal-title":"J Vet Pharmacol and Ther"},{"issue":"10","key":"1128_CR2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2460\/ajvr.2005.66.1770","volume":"66","author":"HW Boothe","year":"2005","unstructured":"Boothe HW, Jones SA, Wilkie WS, Boeckh A, Stenstrom KK, Boothe DM. Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. Am J Vet Res. 2005;66(10):1770\u20134.","journal-title":"Am J Vet Res"},{"issue":"5","key":"1128_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2885.2010.01164.x","volume":"33","author":"H Ding","year":"2010","unstructured":"Ding H, Li Y, Chen Z, Rizwan-ul-Haq M, Zeng Z. Plasma and tissue cage fluid pharmacokinetics of marbofloxacin after intravenous, intramuscular, and oral single-dose application in pigs. J Vet Pharmacol Ther. 2010;33(5):507\u201310.","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"1128_CR4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0924-8579(02)00025-0","volume":"19","author":"P Lees","year":"2002","unstructured":"Lees P, Aliabadi FS. Rational dosing of antimicrobial drugs: animals versus humans. Int J Antimicrob Agents. 2002;19(4):269\u201384.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1128_CR5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vetmic.2009.09.067","volume":"142","author":"YC Wang","year":"2010","unstructured":"Wang YC, Chan JP, Yeh KS, Chang CC, Hsuan SL, et al. Molecular characterization of enrofloxacin resistant Actinobacillus pleuropneumoniae isolates. Vet micro. 2010;142(3):309\u201312.","journal-title":"Vet micro."},{"issue":"6","key":"1128_CR6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/jvp.12134","volume":"37","author":"C Vilalta","year":"2014","unstructured":"Vilalta C, Giboin H, Schneider M, El Garch F, Fraile L. Pharmacokinetic\/pharmacodynamic evaluation of marbofloxacin in the treatment of Haemophilus parasuis and Actinobacillus pleuropneumoniae infections in nursery and fattener pigs using Monte Carlo simulations. J Vet Pharmacol Ther. 2014;37(6):542\u20139.","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"1128_CR7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jvp.12207","volume":"38","author":"P Lees","year":"2015","unstructured":"Lees P, Pelligand L, Illambas J, Potter T, Lacroix M, Rycroft A, et al. Pharmacokinetic\/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. J Vet Pharmacol Ther. 2015;38(5):457\u201370.","journal-title":"J Vet Pharmacol Ther"},{"issue":"6","key":"1128_CR8","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","volume":"56","author":"MN Martinez","year":"2012","unstructured":"Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795\u2013805.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1128_CR9","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","volume":"18","author":"JW Mouton","year":"2012","unstructured":"Mouton JW, Brown DF, Apfalter P, Cant\u00f3n R, Giske CG, Ivanova M, et al. The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18(3):E37\u201345.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"1128_CR10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","volume":"14","author":"JW Mouton","year":"2011","unstructured":"Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Update. 2011;14(2):107\u201317.","journal-title":"Drug Resist Update"},{"issue":"10","key":"1128_CR11","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","volume":"55","author":"EI Nielsen","year":"2011","unstructured":"Nielsen EI, Cars O, Friberg LE. Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother. 2011;55(10):4619\u201330.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1128_CR12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/pr.111.005769","volume":"65","author":"EI Nielsen","year":"2013","unstructured":"Nielsen EI, Friberg LE. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacol Rev. 2013;65(3):1053\u201390.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1128_CR13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vetmic.2013.12.021","volume":"171","author":"MG Papich","year":"2014","unstructured":"Papich MG. Pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs. Vet micro. 2014;171(3):480\u20136.","journal-title":"Vet micro"},{"issue":"2","key":"1128_CR14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2460\/ajvr.75.2.124","volume":"75","author":"JF Rey","year":"2014","unstructured":"Rey JF, Laffont CM, Croubels S, De Backer P, Zemirline C, Bousquet E, et al. Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs. Am J Vet Res. 2014;75(2):124\u201331.","journal-title":"Am J Vet Res"},{"key":"1128_CR15","doi-asserted-by":"crossref","unstructured":"Toutain PL, Potter T, Pelligand L, Lacroix M, Illambas J, Lees P. Standard PK\/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf. Journal of veterinary pharmacology and therapeutics. 2017;40(1):16\u201327.","DOI":"10.1111\/jvp.12333"},{"issue":"5","key":"1128_CR16","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.ajic.2006.05.227","volume":"34","author":"MJ Rybak","year":"2006","unstructured":"Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J infec control. 2006;34(5):S38\u201345.","journal-title":"Am J infec control"},{"issue":"4","key":"1128_CR17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","volume":"23","author":"ME Levison","year":"2009","unstructured":"Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin N Am. 2009;23(4):791\u2013815.","journal-title":"Infect Dis Clin N Am"},{"key":"1128_CR18","unstructured":"CLSI (2013) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals: Approved Standard - Fourth Edition. CLSI document VET01-A4 (formerly M31-A3, 2008) Supplementary information VET01-S, 2015. ISBN 1\u201356238\u2013877-0 [print]; ISBN 1\u201356238\u2013878-9 [electronic]. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2013."},{"issue":"12","key":"1128_CR19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2460\/ajvr.2001.62.1979","volume":"62","author":"FS Aliabadi","year":"2001","unstructured":"Aliabadi FS, Lees P. Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. Am J Vet Res. 2001 Dec 1;62(12):1979\u201389.","journal-title":"Am J Vet Res"},{"issue":"2","key":"1128_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tvjl.2009.02.009","volume":"184","author":"PK Sidhu","year":"2010","unstructured":"Sidhu PK, Landoni MF, AliAbadi FS, Lees P. Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats. Vet J. 2010;184(2):219\u201329.","journal-title":"Vet J"},{"issue":"3","key":"1128_CR21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jvp.12093","volume":"37","author":"P Sidhu","year":"2014","unstructured":"Sidhu P, Rassouli A, Illambas J, Potter T, Pelligand L, Rycroft A, et al. Pharmacokinetic\u2013pharmacodynamic integration and modelling of florfenicol in calves. J Vet Pharmacol Ther. 2014;37(3):231\u201342.","journal-title":"J Vet Pharmacol Ther"},{"issue":"7","key":"1128_CR22","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.01433-10","volume":"55","author":"MA Zeitlinger","year":"2011","unstructured":"Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, et al. Protein Binding: Do We Ever Learn? Antimicrob Agents Chemother. 2011;55(7):3067\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1128_CR23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/vr.100935","volume":"171","author":"C Brentnall","year":"2012","unstructured":"Brentnall C, Cheng Z, McKellar QA, Lees P. Pharmacodynamics of oxytetracycline administered alone and in combination with carprofen in calves. Vet Rec. 2012;171(11):273\u20137.","journal-title":"Vet Rec"},{"key":"1128_CR24","doi-asserted-by":"publisher","unstructured":"Dorey L, Hobson S, Lees P. What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens A. pleuropneumoniae and P. multocida? J Vet Pharmacol Ther. 2016; Doi: 10.1111\/jvp.12386","DOI":"10.1111\/jvp.12386"},{"issue":"3","key":"1128_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2885.2002.00399.x","volume":"25","author":"FS Aliabadi","year":"2002","unstructured":"Aliabadi FS, Lees P. Pharmacokinetics and pharmacokinetic\/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. J Vet Pharmacol Ther. 2002;25(3):161\u201374.","journal-title":"J Vet Pharmacol Ther"},{"key":"1128_CR26","first-page":"22","volume":"8","author":"P Lees","year":"2015","unstructured":"Lees P, Pelligand L, Ferran A, Bousquest-Melou A, Toutain P. Application of pharmacological principles to dosage design of antimicrobial drugs. Pharmacol mat. 2015;8:22.","journal-title":"Pharmacol mat"},{"key":"1128_CR27","doi-asserted-by":"publisher","unstructured":"Dorey L, Hobson S, Lees P. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: comparison of growth media. Res Vet Sci. 2016. Doi: 10.1016\/j.rvsc.2016.11.001 .","DOI":"10.1016\/j.rvsc.2016.11.001"},{"key":"1128_CR28","doi-asserted-by":"publisher","unstructured":"Dorey L, Hobson S, Lees P. Part 2: Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Res Vet Sci 2016; Doi: 10.1016\/j.rvsc.2016.11.001 .","DOI":"10.1016\/j.rvsc.2016.11.001"},{"issue":"1","key":"1128_CR29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vetmic.2014.04.008","volume":"172","author":"A Jong de","year":"2014","unstructured":"de Jong A, Thomas V, Simjee S, Moyaert H, El Garch F, Maher K, et al. Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath study. Vet Microbiol. 2014;172(1):202\u201315.","journal-title":"Vet Microbiol"},{"issue":"s2","key":"1128_CR30","doi-asserted-by":"crossref","first-page":"2S27","DOI":"10.1111\/j.1469-0691.1998.tb00692.x","volume":"4","author":"G Drusano","year":"1998","unstructured":"Drusano G, Labro MT, Cars O, Mendes P, Shah P, S\u00f6rgel F, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect. 1998;4(s2):2S27\u201341.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1128_CR31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1086\/514623","volume":"27","author":"H Lode","year":"1998","unstructured":"Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998;27(1):33\u20139.","journal-title":"Clin Infect Dis"},{"issue":"Supplement 1","key":"1128_CR32","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","volume":"45","author":"GL Drusano","year":"2007","unstructured":"Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007;45(Supplement 1):S89\u201395.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1128_CR33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2885.2004.00613.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. J Vet Pharmacol Ther. 2004;27(6):467\u201377.","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"1128_CR34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2013.07.008","volume":"42","author":"AA Ferran","year":"2013","unstructured":"Ferran AA, Bibbal D, Pellet T, Laurentie M, Gicquel-Bruneau M, Sanders P, et al. Pharmacokinetic\/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model. Int J Antimicrob Agents. 2013;42(5):429\u201335.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1128_CR35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2885.2011.01350.x","volume":"35","author":"M Vall\u00e9","year":"2012","unstructured":"Vall\u00e9 M, Schneider M, Galland D, Giboin H, Woehrle F. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease. J Vet Pharmacol Ther. 2012;35(6):519\u201328.","journal-title":"J Vet Pharmacol Ther"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-017-1128-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T23:42:11Z","timestamp":1569627731000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-017-1128-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1186\/s12917-017-1128-y","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]},"article-number":"209"}}